Bobby G. Soni

Directeur/Membre du Conseil chez MISSION Therapeutics Ltd.

Profil

Bobby G.
Soni currently works at Autifony Therapeutics Ltd., as Non-Executive Director, MISSION Therapeutics Ltd., as Director, Pulmocide Ltd., as Director, Enterprise Therapeutics Ltd., as Non-Executive Director from 2018, and STORM Therapeutics Ltd., as Director.
Dr. Soni also formerly worked at Avilex Pharma ApS, as Chairman, Novo Holdings A, as Investment Director, Touchstone Innovations Investment Management Ltd., as Director, Novo Seeds, as Investment Director from 2013 to 2015, Strategic Partners A, as Director, Caerus Consulting AS, as Director, Aros Pharma ApS, as Director, Contera Pharma ApS, as Director, Nanoference ApS, as Director, Acesion Pharma ApS, as Director, Auspherix Ltd., as Non-Executive Director, Oxular Ltd., as Non-Executive Director, Artios Pharma Ltd., as Non-Executive Director, IP Group Plc, as Partner from 2015 to 2019, LEO Pharma A, as Manager-Discovery Licensing, Maxygen ApS, as Project Leader & Principal Scientist, and Bioinnovation Institute, as Chief Business Officer from 2019 to 2025.
Dr. Soni received his undergraduate degree in 1992 from Rochester Christian University and doctorate degree in 1998 from the University of Virginia.

Postes actifs de Bobby G. Soni

Sociétés	Poste	Début
MISSION Therapeutics Ltd.	Directeur/Membre du Conseil	-
STORM Therapeutics Ltd.	Directeur/Membre du Conseil	-
Pulmocide Ltd.	Directeur/Membre du Conseil	-
Enterprise Therapeutics Ltd.	Directeur/Membre du Conseil	06/04/2018
Autifony Therapeutics Ltd.	Directeur/Membre du Conseil	-

Anciens postes connus de Bobby G. Soni

Sociétés	Poste	Fin
Bioinnovation Institute	Private Equity Investor	02/04/2025
IP GROUP PLC	Corporate Officer/Principal	01/10/2019
Auspherix Ltd.	Directeur/Membre du Conseil	30/04/2019
Novo Seeds	Corporate Officer/Principal	31/08/2015
░░░░░░ ░░░░	░░░░░░░░░░░░░░░░ ░░ ░░░░░░░	-